Financial reports
Current reports
8-K
Termination of a Material Definitive Agreement
26 Feb 24
8-K
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
26 Dec 23
8-K
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
1 Nov 23
8-K
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full
19 Sep 23
Registration and prospectus
15-12G
Securities registration termination
7 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Feb 24
25-NSE
Exchange delisting
26 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
23 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
23 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
16 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
14 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
12 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
12 Feb 24
SC 14D9
Tender offer solicitation
25 Jan 24
Proxies
No filings
Other
EFFECT
Notice of effectiveness
15 Sep 23
CERT
Certification of approval for exchange listing
14 Sep 23
SEC STAFF LETTER
SEC staff letter
14 Sep 23
CORRESP
Correspondence with SEC
12 Sep 23
CORRESP
Correspondence with SEC
12 Sep 23
CORRESP
Correspondence with SEC
11 Sep 23
UPLOAD
Letter from SEC
7 Sep 23
CORRESP
Correspondence with SEC
1 Sep 23
UPLOAD
Letter from SEC
29 Aug 23
CORRESP
Correspondence with SEC
24 Aug 23
Ownership
4
OLE ANDREAS HALVORSEN
28 Feb 24
4
OLE ANDREAS HALVORSEN
28 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
28 Feb 24
4
Christy J. Oliger
27 Feb 24
4
Angie You
27 Feb 24
4
Hauwermeiren Timothy Van
27 Feb 24
4
MARY TAGLIAFERRI
27 Feb 24
4
Richard A. Heyman
27 Feb 24
4
Yi Larson
27 Feb 24
4
Maha Katabi
27 Feb 24